ARCHIVES

NCI Closes Iressa Trial For NSCLC When Data Indicate No Survival Benefit

This article is from The Cancer Letter archive.

Vol. 28 No. 4 | April 29, 2005

Download PDF Visit The Full Archive

Related Articles

Zytiga and Prednisone Extends Overall Survival in mCRPC Trial

October 31, 2014

Gallo’s Lab Moved From DCT to DCE; NCI Planning To Drop “Cancer Treatment Reports” At End Of ‘86

February 6, 1987

Zometa Better Than Placebo In Treatment Of Bone Mets

August 31, 2001

William Nelson Named Cancer Center Director At Johns Hopkins.

November 7, 2008

NIH Responds To IOM Report On Women’s Health Initiative

November 12, 1993

In Brief: Jane Henney Sworn In As FDA Commissioner; Six Centers Retain Comprehensive Status

December 18, 1998